AMAmgen AMGN · NASDAQ
$460.73 +1.97% (+$8.90)
- Market cap
- $249.1B
- Enterprise value
- $292.4B
- P/E
- 28.5x
- Forward P/E
- 19.9x
- PEG
- 0.4x
- P/S
- 6.5x
- P/FCF
- 24.5x
- EV/EBITDA
- 17.7x
- ROIC
- 14.2%
- Bruto marža
- 72.7%
- Neto marža
- 22.9%
- Dividend yield
- 2.16%
- Payout ratio
- 61.5%
- Neto dolg/EBITDA
- 2.6x
- Beta
- 0.41
- Free float
- 99.7%
O podjetju
Amgen Inc. is an American biotechnology company specializing in research, development, and manufacturing of biologic medicines. The company focuses on innovative therapeutic treatments for various diseases, including cancer, cardiovascular conditions, arthritis, and other serious illnesses. Amgen has developed a range of successful drugs that have transformed the lives of patients worldwide. The company also invests in research for new drugs and treatment approaches to better address current and future healthcare challenges. Amgen collaborates with physicians, scientists, and other experts to improve healthcare and develop new therapeutic options. Amgen Inc. (AMGN) shares are an interesting choice for investors who follow the biotechnology sector and seek investment opportunities in a reputable company that brings innovative therapeutic treatments for serious diseases.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert A. Bradway
Employees
31,500
Headquarters
Thousand Oaks
Vrednotenje
Je današnja cena primerna?
- Na kaj bodite pozorni: Cena delnice je nad Bulios Fair Price.
Rast in ocene
Ali podjetje raste in kaj sledi?
- Kaj govori v prid: Prihodki so v zadnjih 3 letih rasli za 12 % letno.
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
- Kaj govori v prid: Od vsakih 100 USD prihodkov ostane 23 USD čistega dobička.
- Kaj govori v prid: Na vsakih 100 USD vloženega kapitala zasluži 14 USD letno.
Finančno zdravje
Ali zmore svoj dolg?
- Na kaj bodite pozorni: Na vsakih 100 USD lastniškega kapitala ima 490 USD dolga.
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
- Kaj govori v prid: Dividendo zvišuje že 14 let zapored.
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke